Literature DB >> 27540427

Conspicuity of FDG-Avid Osseous Lesions on PET/MRI Versus PET/CT: a Quantitative and Visual Analysis.

Tyler J Fraum1, Kathryn J Fowler1, Jonathan McConathy1.   

Abstract

BACKGROUND: Because standard MRI-based attenuation correction (AC) does not account for the attenuation of photons by cortical bone, PET/MRI may have reduced sensitivity for FDG-avid focal bone lesions (FFBLs). This study evaluates whether MRI-based AC compromises detection of FFBLs, by comparing their conspicuity both quantitatively and qualitatively on PET/MRI versus PET/CT.
METHODS: One hundred ninety general oncology patients underwent whole-body PET/CT followed by whole-body PET/MRI, utilizing the same FDG dose. Thirteen patients with a total of 50 FFBLs were identified. Using automated contouring software, a volumetric contour was generated for each FFBL. Adjacent regions of normal background bone (BB) were selected manually. For each contour, SUV-max and SUV-mean were determined. Lesion-to-background SUV ratios served as quantitative metrics of conspicuity. Additionally, two blinded readers evaluated the relative conspicuity of FFBLs on PET images derived from MRI-based AC versus CT-based AC. Visibility of an anatomic correlate for FFBLs on the corresponding CT and MR images was also assessed.
RESULTS: SUV-mean was lower on PET/MRI for both FFBLs (-6.5 %, p = 0.009) and BB (-20.5 %, p < 0.001). SUV-max was lower on PET/MRI for BB (-14.2 %, p = 0.002) but not for FFBLs (-6.2 %, p = 0.068). The ratio of FFBL SUV-mean to BB SUV-mean was higher for PET/MRI (+29.5 %, p < 0.001). Forty of 50 lesions (80 %) were visually deemed to be of equal or greater conspicuity on PET images derived from PET/MRI. Thirty-five of 50 FFBLs (70 %) had CT correlates, while 40/50 FFBLs (80 %) had a correlate on at least one MRI sequence. The mean interval from tracer administration to imaging was longer (p < 0.001) for PET/MRI (127 v. 62 min).
CONCLUSIONS: Both FFBLs and BB had lower mean SUVs on PET/MRI than PET/CT. This finding was likely in part due to differences in the handling of cortical bone by MRI-based AC versus CT-based AC. Despite this systematic bias, FFBLs had greater conspicuity on PET/MRI, both qualitatively and quantitatively. This difference was likely due to the longer tracer uptake times for PET/MRI, which allowed for more tracer accumulation by FFBLs and more tracer washout from BB. Our results suggest that whole-body PET/MRI and PET/CT provide comparable sensitivity for detection of FDG-avid focal bone lesions.

Entities:  

Keywords:  Clinical oncology; Magnetic resonance imaging; Multimodal imaging; Positron emission tomography; Whole-body imaging

Year:  2016        PMID: 27540427      PMCID: PMC4977253          DOI: 10.1007/s13139-016-0403-3

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  21 in total

Review 1.  Kappa coefficients in medical research.

Authors:  Helena Chmura Kraemer; Vyjeyanthi S Periyakoil; Art Noda
Journal:  Stat Med       Date:  2002-07-30       Impact factor: 2.373

Review 2.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

3.  Fusion of PET and MRI for staging of uterine cervical cancer: comparison with contrast-enhanced (18)F-FDG PET/CT and pelvic MRI.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Yoshiko Ueno; Tomonori Kanda; Tetsuo Maeda; Masashi Deguchi; Yasuhiko Ebina; Hideto Yamada; Satoru Takahashi; Kazuro Sugimura
Journal:  Clin Imaging       Date:  2014-02-15       Impact factor: 1.605

Review 4.  Radiologic diagnosis of bone metastases.

Authors:  D I Rosenthal
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

Review 5.  Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity.

Authors:  Orazio Schillaci
Journal:  Semin Nucl Med       Date:  2012-07       Impact factor: 4.446

6.  Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT.

Authors:  Gerwin P Schmidt; Stefan O Schoenberg; Rupert Schmid; Robert Stahl; Reinhold Tiling; Christoph R Becker; Maximilian F Reiser; Andrea Baur-Melnyk
Journal:  Eur Radiol       Date:  2006-09-02       Impact factor: 5.315

7.  PET attenuation correction using synthetic CT from ultrashort echo-time MR imaging.

Authors:  Snehashis Roy; Wen-Tung Wang; Aaron Carass; Jerry L Prince; John A Butman; Dzung L Pham
Journal:  J Nucl Med       Date:  2014-11-20       Impact factor: 10.057

8.  Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results.

Authors:  Christian Plathow; Philip Aschoff; Mathias Philip Lichy; Susanne Eschmann; Thomas Hehr; Ingo Brink; Claus D Claussen; Christina Pfannenberg; Heinz-Peter Schlemmer
Journal:  Invest Radiol       Date:  2008-05       Impact factor: 6.016

9.  Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.

Authors:  Philipp Heusch; Christian Buchbender; Karsten Beiderwellen; Felix Nensa; Verena Hartung-Knemeyer; Thomas C Lauenstein; Andreas Bockisch; Michael Forsting; Gerald Antoch; Till A Heusner
Journal:  Eur J Radiol       Date:  2013-02-08       Impact factor: 3.528

10.  Value of fusion of PET and MRI for staging of endometrial cancer: comparison with ¹⁸F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Yoshiko Ueno; Tomonori Kanda; Tetsuo Maeda; Satoru Takahashi; Yasuhiko Ebina; Yoshiya Miyahara; Hideto Yamada; Kazuro Sugimura
Journal:  Eur J Radiol       Date:  2013-05-30       Impact factor: 3.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.